The implications of oncogene expression on cancer drug resistance remain poorly understood, although there have been over 25 oncogenes including KRAS, ERBB2, PIK3CA, AKT hypothesized to contribute to drug resistance in ovarian cancer through various signalling pathways [215, 216, 224]. This evidence concerns the gene PIK3CA and cancer.